Oslo, 10 May 2023 - Navamedic ASA (OSE: NAVA), a Nordic pharma company and
provider of high-quality products to hospitals and pharmacies, has today amended
its cash offer to acquire the shares and warrants in Sensidose AB not already
owned by Navamedic ASA (the "Offer"). The Sensidose shares and warrants of
series TO 1 are currently listed on Spotlight Stock Market in Sweden.

Navamedic ASA ("Navamedic") has today amended its Offer to SEK 8.50 per share in
Sensidose AB ("Sensidose") and extended the acceptance period for the Offer
until 25 May 2023. Navamedic has also offered to acquire the traded warrants of
series TO 1 in Sensidose for SEK 0.60 per warrant.

Navamedic has already acquired 6,928,935 shares in Sensidose representing 57.94%
of the outstanding shares. Navamedic has also acquired 426,577 tradable warrants
of series TO 1 in Sensidose and thereby secured an ownership of more than 50% in
Sensidose even if all subscription rights are exercised.

The Offer represents a valuation of Sensidose of approximately SEK 102 million.
The value of the Offer (i.e. excluding the shares and warrants already owned by
Navamedic) is approximately SEK 44 million.

For further information about the Offer, please see the attached press release
regarding the amended Offer.

Carnegie Investment Bank is acting as financial advisor to Navamedic. Roschier
Advokatbyrå AB and Advokatfirmaet Thommessen AS are acting as legal advisors to
Navamedic. First House AS is acting as communications and IR advisor to
Navamedic.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic

Mobile: +47 951 78 680

E-mail: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic

Mobile: +47 917 62 842

E-mail: lars.hjarrand@navamedic.com

About Navamedic ASA

Navamedic ASA is a Nordic pharma company and reliable provider of high-quality
products, delivered to hospitals and through pharmacies, meeting the specific
needs of patients and consumers by leveraging its highly scalable market access
platform, leading category competence and local knowledge. Navamedic is present
in all the Nordic countries, the Baltics and Benelux, with sales representation
in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on
the Oslo Stock Exchange (ticker: NAVA). For more information, please
visit www.navamedic.com

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to Section 5-12 the Norwegian Securities Trading Act. The information was

submitted for publication, through Newsweb by Lars Hjarrand at 09:00 hrs CET on
10 May 2023.